Citable filing context

ELV filing events and research context

Server-rendered

ELV's research view summarizes recent SEC filing context, starting with management_change from May 13, 2026.

ELV filing events and research context
FiledItemContext
May 13, 2026management_changeElevance Health shareholders elected directors and approved executive compensation at the Annual Meeting on May 13, 2026.
Apr 22, 2026earningsElevance Health reported Q1 2026 adjusted EPS of $12.58 and raised full-year adjusted EPS guidance to at least $26.75.
Mar 10, 2026guidance_updateELV reaffirms 2026 adjusted EPS guidance of at least $25.50 and 90.2% benefit expense ratio.
Apr 22, 2026Guidance: adjusted_diluted_eps26.75 to not reported
Apr 22, 2026Guidance: diluted_eps19.85 to not reported
Apr 22, 2026Guidance: operating_cash_flow5.50 to not reported
Apr 22, 2026mda_quarterlyElevance Health reported a 1.5% increase in total operating revenue to $49.49 billion for Q1 2026, driven by premium rate increases in Health Benefits and growth in CarelonRx product revenues, despite membership attrition. However, shareholders' net income decreased 19.2% to $1.76 billion, with EPS falling 16.8% to $8.00, primarily due to decreased operating gain across all segments and increased interest expense, partially offset by favorable financial instrument and investment income. Operating cash flow significantly improved to $4.33 billion due to favorable working capital. Total medical membership declined 0.9% to 45.4 million, mainly from Medicaid redeterminations and decreases in Medicare Advantage, Employer Group Risk-Based, and Federal Employee Program, partially offset by growth in Employer Group Fee-Based. Medical cost trends remain elevated, particularly in Medicaid due to higher acuity and utilization, and in Individual ACA following Medicaid redetermination shifts. The company faces regulatory impacts from the OBBBA, including PBM reforms and Medicaid changes, and the expiration of enhanced ACA Premium Tax Credits, which may affect Individual market enrollment. CMS issued an intent to impose sanctions for Medicare Advantage risk adjustment data noncompliance, with a compliance deadline extended to July 31, 2026. The Provider Settlement Agreement in the BCBSA Antitrust Litigation became effective in September 2025, with a $666 million payment recognized in September 2024. Elevance Health is implementing a 2026-2027 Operating Model Transformation Program to streamline operations and enhance technology. The company maintains a strong liquidity position with $38.19 billion in cash and investments and a stable 42.0% debt-to-capital ratio.
Feb 6, 2026businessELV operates as a diversified health company, providing health benefits, pharmacy services, and other healthcare offerings like digital health, home health, and behavioral care. Its business critically depends on advanced information systems, including AI and machine learning, which require substantial ongoing investment and expose the company to significant cybersecurity, data integrity, and integration risks, particularly from acquisitions and third-party vendors. The company navigates a highly regulated environment with frequent changes in federal and state laws, such as those related to the ACA, Medicare, and Medicaid, affecting licensing, pricing, and product development. Intense competition across its health benefits and pharmacy services segments drives the need for continuous innovation and revenue diversification. A core dependency is its license agreements with the Blue Cross Blue Shield Association, with potential termination carrying a substantial $3 billion re-establishment fee. Financial stability is also influenced by restrictions on subsidiary dividends, significant indebtedness, potential impairment of its $39.5 billion in goodwill and intangible assets, and investment portfolio volatility. External challenges include public health crises, natural disasters, and negative industry publicity.

Source: SEC EDGAR filing text and events; period May 13, 2026; filed May 13, 2026.

Continue research

Keep researching ELV

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →